Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [5]. Core Insights - The company reported a revenue of 332 million yuan in Q1 2025, a year-on-year decrease of 7%, and a net profit attributable to shareholders of 130 million yuan, down 30% year-on-year [2]. - The domestic market is facing short-term pressure due to changes in the market environment, leading to adjustments in product pricing and promotional strategies, while the overseas market is expanding rapidly with a sales revenue growth of over 93% year-on-year [3]. - The company has set ambitious growth targets in its employee stock ownership plan, aiming for a net profit of no less than 600 million yuan in 2025, reflecting confidence in future operations [4]. Summary by Sections Performance Overview - In Q1 2025, the company achieved a revenue of 332 million yuan, a decrease of 7% year-on-year, and a net profit of 130 million yuan, down 30% year-on-year [2]. Operational Analysis - The domestic market is under pressure, but the company maintains a leading market share in domestic active artery intervention products and is expanding its market coverage for peripheral vascular intervention products. The overseas market has seen a significant increase in sales, with new registrations in three countries and over 100 total overseas product registrations [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 606 million yuan, 794 million yuan, and 965 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 21%, 31%, and 22% [5].

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits of 2.8 billion, 3.2 billion, and 4.0 billion RMB for 2025, 2026, and 2027 respectively, corresponding to PE valuations of 35, 30, and 25 times [4]. Core Insights - The company's revenue for 2024 reached 9.39 billion RMB, a year-on-year increase of 4.51%, with a net profit attributable to shareholders of 2.51 billion RMB, up 0.40% year-on-year. In Q1 2025, revenue was 2.42 billion RMB, reflecting a 2.5% increase year-on-year, while net profit was 618 million RMB, up 2.66% year-on-year [2]. - The recovery in the excavator market, along with the expansion into non-excavator markets, has driven stable revenue growth. The domestic engineering machinery industry showed signs of recovery in 2024, with excavator sales increasing by 3.13% year-on-year. The company's revenue growth was supported by increased market share in hydraulic pump and valve products, diversification into non-engineering machinery products, and successful international market expansion [2][3]. - The company's overall profitability remains stable, with a gross margin of 42.83% in 2024, up 1 percentage point year-on-year, while the net margin was approximately 26.76%, down 1.1 percentage points due to increased sales and management expenses [2]. Summary by Sections Performance Review - In 2024, the company achieved a revenue of 9.39 billion RMB, a 4.51% increase year-on-year, and a net profit of 2.51 billion RMB, a 0.40% increase year-on-year. Q4 2024 revenue was 2.45 billion RMB, with a net profit of 717 million RMB [2]. - For Q1 2025, revenue was 2.42 billion RMB, a 2.5% year-on-year increase, and net profit was 618 million RMB, a 2.66% increase year-on-year [2]. Operational Analysis - The excavator market's recovery and the expansion into non-excavator markets have jointly driven stable revenue growth. In 2024, the company saw a historical high in revenue, attributed to increased market share in hydraulic pump and valve products, ongoing diversification, and successful international market expansion [2][3]. - The revenue breakdown for 2024 included hydraulic cylinders (4.76 billion RMB), hydraulic pumps and valves (3.58 billion RMB), motors (296 million RMB), hydraulic systems (684 million RMB), and parts and castings (1.68 billion RMB), with respective year-on-year growth rates of +1.44%, +9.63%, +1.64%, +1.76% [2]. Profitability - The gross margin for 2024 was 42.83%, an increase of 1 percentage point year-on-year, while the net margin was approximately 26.76%, a decrease of 1.1 percentage points due to increased sales and management expenses [2]. - In Q1 2025, the gross margin was 39.4%, a decrease of 0.69 percentage points year-on-year, and the net margin was 25.55%, remaining stable year-on-year [2].

研发项目顺利推进，持续推进产品技术创新。一季度公司创新研 发管线取得多项成果，Cratos 分支型主动脉覆膜支架系统、 Tipspear 经颈静脉肝内穿刺套件国内获批上市，Hector 胸主动脉 多分支覆膜支架系统获批进入国家创新医疗器械特别审查程序， Aegis II 腹主动脉覆膜支架系统完成上市前临床植入，Fishhawk 机械血栓切除导管完成国内注册资料递交，众多创新产品将推动 公司长期业绩稳定增长。 员工持股计划设置高增长目标，彰显公司发展信心。2024 年 12 月公司公布新一期员工持股计划，将 2025 年~2027 年作为业绩考 核年度，分别要求 2025 年净利润不低于 6 亿元、2025-2026 年净 利润累计不低于 13.2 亿元、2025-2027 年净利润累计不低于 21.84 亿元，利润逐年同比增速目标在 20%，高增长目标彰显了公司对未 来经营的信心。 业绩简述 2025 年 4 月 29 日，公司发布 2025 年第一季度报告，2025Q1 公司 实现收入 3.32 亿元，同比-7%；归母净利润 1.30 亿元，同比-30%； 扣非归母净利润 1.22 亿元，同比-31%。 经 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [6][14]. Core Insights - The company reported a revenue of 8.978 billion RMB for 2024, representing a year-on-year growth of 9.69%, and a net profit of 695 million RMB, up 19.81% [2]. - For Q1 2025, the company achieved a revenue of 2.605 billion RMB, a significant increase of 36.47%, with a net profit of 249 million RMB, also up 36.26% [2]. - The company is expected to benefit from dual growth drivers in the consumer goods and medical sectors [2]. Performance Analysis - The consumer goods segment showed strong growth, with Q4 2024 revenue reaching 2.908 billion RMB, a 33.72% increase [3]. - For 2024, the medical supplies and consumer goods segments generated revenues of 3.906 billion RMB and 4.991 billion RMB, growing by 1.14% and 17.09% respectively [3]. - Key product categories such as cotton soft towels and children's clothing saw revenue increases of 31.19% and 13.21% respectively [3]. Q1 2025 Development - In Q1 2025, the medical segment generated 1.25 billion RMB, a 46.3% increase, with core categories like surgical supplies and high-end dressings showing remarkable growth [4]. - The consumer segment achieved 1.34 billion RMB in revenue, up 28.8%, with the "Princess Nais" sanitary napkin leading the category with a 73.5% increase [4]. - E-commerce contributed 59.9% of total revenue, with rapid growth in supermarket channels, which saw a 70.9% year-on-year increase [4]. Profitability - The gross margin for 2024 and Q1 2025 was 48.46% and 47.32% respectively, with a slight improvement in Q1 2025 due to product mix optimization [5]. - The net profit margin remained stable at 7.75% for 2024 and improved to 9.54% in Q1 2025 [5]. - The company aims to enhance brand strength and operational efficiency while focusing on core product categories [5]. Earnings Forecast and Valuation - The company is projected to have EPS of 1.80, 2.12, and 2.54 RMB for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 27, 23, and 19 [6].

1. Report Industry Investment Rating - Not provided in the content 2. Core Viewpoints of the Report - As of April 28, 2025, in the stock of credit bonds, the valuation yields and spreads of private enterprise industrial bonds are generally higher than those of other varieties. The yields of most non - financial and non - real estate industrial bonds have increased, while the yields of private and public non - perpetual bonds of private enterprises within 1 year have decreased. In real estate bonds, except for private bonds within 1 year and public non - perpetual bonds within 2 years, the yields of other varieties have increased to varying degrees. In financial bonds, the yields of most varieties have increased, with leasing company bonds and urban and rural commercial bank capital supplementary tools having relatively high valuation yields and spreads [3][8]. 3. Summary by Relevant Catalogs 3.1 General Situation of Stock Credit Bonds - As of April 28, 2025, the valuation yields and spreads of private enterprise industrial bonds in the stock of credit bonds are generally higher than those of other varieties. Compared with last week, the yields of most non - financial and non - real estate industrial bonds have increased, especially those of varieties over 1 year, with adjustments generally within 10bp. The yields of private and public non - perpetual bonds of private enterprises within 1 year have decreased by 10.2bp and 4.3bp respectively. In real estate bonds, except for private bonds within 1 year and public non - perpetual bonds within 2 years, the yields of other varieties have increased to varying degrees. In financial bonds, the varieties with high valuation yields and spreads are leasing company bonds and urban and rural commercial bank capital supplementary tools. Compared with last week, the yields of most financial bond varieties have increased [3][8]. 3.2 Urban Investment Bonds 3.2.1 Public Urban Investment Bonds - The weighted average valuation yields of public urban investment bonds in Jiangsu and Zhejiang provinces are both below 2.6%. Urban investment bonds with yields exceeding 4.5% are found in prefecture - level and district - county - level areas of Guizhou. In other regions, the spreads in Yunnan, Gansu, Inner Mongolia and other places are also relatively high. Compared with last week, the performance of public urban investment bonds has differentiated among different terms. The average decline of varieties within 1 year is close to 0.2BP, while the yields of medium - and long - term bonds have mostly increased. The varieties with relatively large yield declines include non - perpetual bonds of prefecture - level cities in Guizhou with a term of 2 - 3 years, perpetual bonds of district - county - level areas in Shaanxi within 1 year, non - perpetual bonds of district - county - level areas in Yunnan with a term of 1 - 2 years, and non - perpetual bonds of district - county - level areas in Liaoning within 1 year [2][13]. 3.2.2 Private Urban Investment Bonds - The weighted average valuation yields of private urban investment bonds in coastal provinces such as Shanghai, Zhejiang, Guangdong, and Fujian are below 3.1%. Varieties with yields higher than 4.5% are found in prefecture - level cities of Guizhou, Yunnan, and Liaoning. The spreads in Shaanxi, Hebei, Gansu and other places are also relatively high. Compared with last week, the proportion of yield increases of private urban investment bonds is relatively high, but there are also many cases of yield declines in varieties within 1 year. The varieties with relatively large yield declines include non - perpetual bonds of provincial - level in Shandong within 1 year, perpetual bonds of prefecture - level cities in Jiangxi with a term of 2 - 3 years, non - perpetual bonds of prefecture - level cities in Liaoning within 1 year, and non - perpetual bonds of district - county - level areas in Liaoning with a term of 2 - 3 years, with declines all exceeding 15bp [2][22]. 3.3 Industrial Bonds - The valuation yields and spreads of private enterprise industrial bonds in the stock of credit bonds are generally higher than those of other varieties. Compared with last week, the yields of most non - financial and non - real estate industrial bonds have increased, especially those of varieties over 1 year, with adjustments generally within 10bp. The yields of private and public non - perpetual bonds of private enterprises within 1 year have decreased by 10.2bp and 4.3bp respectively. In real estate bonds, except for private bonds within 1 year and public non - perpetual bonds within 2 years, the yields of other varieties have increased to varying degrees [3][8]. 3.4 Financial Bonds - The varieties with high valuation yields and spreads in financial bonds are leasing company bonds and urban and rural commercial bank capital supplementary tools. Compared with last week, the yields of most financial bond varieties have increased. Specifically, in leasing bonds, the yields of public non - perpetual bonds with a term of 1 - 3 years have increased by more than 5bp, while the yields of private perpetual varieties within 1 year have declined significantly. In commercial financial bonds, the yields of national and joint - stock banks and urban commercial banks within 1 year have slightly decreased, while the bonds of other terms have generally adjusted, with the 1 - 2 year term being the period with the largest correction. The yields of bank sub - bonds have basically increased, but except for the perpetual bonds of rural commercial banks with a term of 2 - 3 years and the secondary bonds of joint - stock banks with a term of 3 - 5 years, the yield increases of other varieties are below 5bp. In addition, private non - perpetual and public perpetual sub - bonds of securities companies within 1 year are favored [4][8].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5][12]. Core Insights - In 2024, the company achieved a revenue of 2.849 billion RMB, a year-on-year increase of 5.08%, but the net profit attributable to shareholders decreased by 4.05% to 226 million RMB [2]. - The semiconductor equipment market is expected to see strong demand, with projected net profits for 2025, 2026, and 2027 at 328 million RMB, 491 million RMB, and 669 million RMB respectively, reflecting growth rates of 44.77%, 49.78%, and 36.22% [5][9]. - The company is focusing on clean application materials and high-purity materials, with significant growth in the semiconductor sector, which saw a revenue increase of 29.9% in 2024 [4]. Summary by Sections Financial Performance - In Q1 2025, the company reported a slight revenue decline of 2.33% year-on-year, with a net profit decrease of 25.56% [2][3]. - The comprehensive gross margin for 2024 was 25.72%, while Q1 2025 saw a decline to 23.82% [3]. - The company’s revenue for 2024 was 2.849 billion RMB, with a projected revenue of 3.506 billion RMB for 2025, indicating a growth rate of 23.04% [9]. Market Outlook - The report highlights a strong demand for semiconductor equipment in China, which is expected to drive domestic production and market share recovery for the company [4][5]. - The food and pharmaceutical sectors are showing moderate recovery, with revenues of 1.680 billion RMB and 305 million RMB respectively in 2024 [4]. Valuation Metrics - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.80 RMB, 1.20 RMB, and 1.64 RMB respectively, with corresponding price-to-earnings (P/E) ratios of 39, 26, and 19 [5][9].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [4]. Core Insights - The company reported a revenue of 2.52 billion yuan for Q1 2025, a year-on-year decrease of 5.88%, but achieved a net profit of 0.66 billion yuan, turning from loss to profit mainly due to increased exchange gains from the rising Japanese yen [2]. - For the full year 2024, the company achieved a revenue of 11.14 billion yuan, a year-on-year growth of 59.99%, primarily due to the acquisition of Zhiming Software in November 2023, which expanded the consolidation scope [2]. - The net profit for 2024 was 1.24 billion yuan, a year-on-year increase of 43.65%, largely attributed to the transfer of equity in Beijing Reyun, which confirmed an investment income of 0.26 billion yuan [2]. - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 0.78 billion yuan, which accounts for 62.74% of the 2024 net profit [2]. Revenue and Profit Analysis - In 2024, the company's revenue from software development services in Japan reached 10.21 billion yuan, a year-on-year increase of 71.31%, with a gross margin of 31.59%, down 4.01 percentage points from the previous year [3]. - The Japanese subsidiary Zhiming generated revenue of 4.37 billion yuan, handling nearly 50% of the external outsourcing volume for the Nomura Research Institute's THE STAR system and about 80% for the I-STAR system [3]. - The domestic industry application software solutions segment saw a revenue decline of 8.58% to 0.91 billion yuan, influenced by the market conditions and IT investment pace of domestic brokerages [3]. Future Projections - Revenue projections for 2025 to 2027 are estimated at 12.18 billion yuan, 13.56 billion yuan, and 15.22 billion yuan, reflecting year-on-year growth rates of 9.28%, 11.35%, and 12.27% respectively [4]. - The expected net profits for the same period are 1.62 billion yuan, 2.00 billion yuan, and 2.46 billion yuan, corresponding to price-to-earnings ratios of 30.25, 24.44, and 19.87 [4].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company reported a revenue of 663 million yuan in Q1 2025, a year-on-year increase of 0.03%, and a net profit attributable to shareholders of 92 million yuan, up 1.65% year-on-year. The gross margin and net margin improved to 36.83% and 12.89%, respectively, reflecting a significant enhancement in profitability [1] - The company benefits from the rising demand in the "two machines" industry, with contract liabilities exceeding 1.2 billion yuan, indicating strong revenue growth potential for 2025. The domestic orders are expected to increase due to accelerated localization efforts in gas turbines and aviation engines [2] - The approval of nuclear power projects is expected to boost the company's revenue from nuclear main pump castings, with strategic partnerships and contracts already in place for multiple nuclear projects [3] Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 663 million yuan and a net profit of 92 million yuan, with improved profitability metrics [1] Operational Analysis - The company signed long-term agreements with major clients in the "two machines" sector, leading to a significant increase in contract liabilities, which grew over 100% year-on-year to 1.76 billion yuan. This positions the company for accelerated revenue growth in 2025 [2] - The domestic market for gas turbines is expanding, with successful certification of domestically developed aircraft engines, indicating a positive trend for future orders [2] Nuclear Power Sector - The approval of five nuclear power projects is expected to enhance demand for the company's nuclear pump products, with existing contracts already in place for significant deliveries [3] Profit Forecast and Valuation - Projected revenues for 2025-2027 are 3.2 billion, 3.9 billion, and 5 billion yuan, with net profits of 450 million, 630 million, and 890 million yuan, respectively. The corresponding price-to-earnings ratios are 30, 22, and 15 [4]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5][12]. Core Insights - The company reported a revenue of 2.786 billion RMB for 2024, representing a year-on-year growth of 25.9%, with a net profit of 180 million RMB, up 16.8% year-on-year [2]. - In Q1 2025, the company achieved a revenue of 864 million RMB, a 22.5% increase year-on-year, and a net profit of 73.77 million RMB, reflecting a significant growth of 47.0% [2]. - The growth in revenue is primarily driven by personalized education services, with training service fees reaching 2.697 billion RMB in 2024, a 25.64% increase [3]. - The company expanded its personalized learning centers from over 240 to more than 300, covering over 100 cities and employing more than 4,000 teachers [3]. - The company has improved its profit margins, with a net profit margin of 8.07% in 2024, up 0.49 percentage points year-on-year, and a projected increase in profitability due to enhanced utilization of offline learning networks [4]. Financial Projections - The company is projected to achieve net profits of 231 million RMB, 285 million RMB, and 344 million RMB for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.898, 2.342, and 2.827 RMB [5][10]. - The company's current PE ratios are estimated at 28, 23, and 19 for the years 2025, 2026, and 2027 respectively [5].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4][13]. Core Views - The company reported a significant decline in revenue and net profit for 2024, with revenue at 1.075 billion RMB, down 11.87% year-on-year, and net profit at 309 million RMB, down 68.61% year-on-year [2][4]. - The first quarter of 2025 showed a recovery in revenue, reaching 325 million RMB, up 52.53% year-on-year, primarily due to the consolidation of Shenzhen Jianyuan and a recovery in cement sales [2][3]. - The private equity business is expected to recover as project exits accelerate, with potential excess performance compensation of 1.023 billion RMB anticipated by the end of 2024 [3][4]. Summary by Sections Performance Overview - In Q4 2024, the company achieved total revenue of 330 million RMB and net profit of 65 million RMB, reflecting declines of 20.16% and 79.56% year-on-year, respectively [2]. - The decline in 2024 was attributed to capital market fluctuations affecting the fair value of invested projects and a significant drop in sales volume and prices in the building materials sector [2]. Business Segments - Private equity business revenue for 2024 was 452 million RMB, down 2.93% year-on-year, with expectations of declining management fee income as project exits accelerate [3]. - The building materials segment generated 594 million RMB in revenue for 2024, down 21.19% year-on-year, due to weak market demand in real estate and infrastructure [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 650 million RMB, 990 million RMB, and 1.376 billion RMB for 2025, 2026, and 2027, respectively, with growth rates of 111%, 52%, and 39% [4]. - A price-to-earnings ratio of 28 times is applied for the year 2025 [4].